title: Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study).
abstract: Nicotinamide has been recently introduced, in addition to intensive insulin therapy for patients with recent-onset insulin-dependent diabetes mellitus (IDDM) to protect beta cells from end-stage destruction. However, available data are conflicting. A double blind trial in 56 newly-diagnosed IDDM patients receiving nicotinamide for 12 months at a dose of 25 mg/kg body weight or placebo was designed in order to determine whether this treatment could improve the integrated parameters of metabolic control (insulin dose, glycated haemoglobin and C-peptide secretion) in the year after diagnosis. In addition to nicotinamide or placebo, patients received three to four insulin injections daily to optimize blood glucose levels. Patients treated with nicotinamide or placebo received similar doses of insulin during follow-up and 1 year after diagnosis with comparable glycated haemoglobin levels 6.7 +/- 1.8% nicotinamide vs 7.1 +/- 0.6% placebo). Basal and glucagon stimulated C-peptide secretion detectable at diagnosis were similarly preserved in the course of 12 months follow-up both in nicotinamide and placebo treated patients. No adverse effects were observed in patients receiving nicotinamide. When age at diagnosis was taken into account, nicotinamide treated older patients ( > 15 years of age) showed significantly higher stimulated C-peptide secretion than placebo treated patients (p < 0.02). These results suggest that nicotinamide can preserve and improve stimulated beta-cell function only in patients diagnosed after puberty.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: II Clinica Medica, Policlinico Umberto I, Rome, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Pozzilli
authors.forename: N
authors.initials: N
authors.lastname: Visalli
authors.forename: A
authors.initials: A
authors.lastname: Signore
authors.forename: M G
authors.initials: MG
authors.lastname: Baroni
authors.forename: R
authors.initials: R
authors.lastname: Buzzetti
authors.forename: M G
authors.initials: MG
authors.lastname: Cavallo
authors.forename: M L
authors.initials: ML
authors.lastname: Boccuni
authors.forename: D
authors.initials: D
authors.lastname: Fava
authors.forename: C
authors.initials: C
authors.lastname: Gragnoli
authors.forename: D
authors.initials: D
authors.lastname: Andreani
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000704:Analysis of Variance; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D002096:C-Peptide / Q000097:blood; D002648:Child; D002675:Child, Preschool; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use*; D007515:Islets of Langerhans / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D008297:Male; D009536:Niacinamide / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos; D013997:Time Factors
chemical_list: D001786:Blood Glucose; D002096:C-Peptide; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D009536:Niacinamide; D010919:Placebos